Study Protocol for a Randomized, Double-Blind, Placebo-Controlled, Phase-II Trial: AdrenoMedullin for Ischemic Stroke Study

• Published in: Journal of stroke and cerebrovascular diseases Vol. 30; no. 6; p. 105761
• Main Authors: Yoshimoto, Takeshi, Saito, Satoshi, Omae, Katsuhiro, Hattori, Yorito, Fukuma, Kazuki, Kitamura, Kazuo, Kakuta, Ryosuke, Kita, Toshihiro, Maruyama, Hirofumi, Yamamoto, Haruko, Ihara, Masafumi
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-06-2021
• Subjects: Adrenomedullin; Clinical trial; Ischemic stroke; Peptide; Protocols; Treatment; Adrenomedullin; Clinical trial; Protocols; Treatment; Ischemic stroke; Peptide
• ISSN: 1052-3057; 1532-8511
• DOI: 10.1016/j.jstrokecerebrovasdis.2021.105761

•A clinical trial of adrenomedullin for ischemic stroke (AMFIS) is being planned.•The AMFIS study is a randomized, double-blind, placebo-controlled phase II trial.•Adrenomedullin is a highly conserved vasoactive peptide with angiogenic properties.•Adrenomedullin is expected to be a novel treatment for acute ischemic stroke.
Adrenomedullin (AM), a vasoactive peptide, has strong anti-inflammatory and angiogenic properties, which have been reported to ameliorate the consequences of ischemic stroke in several animal models. After a phase I study in healthy volunteers, two phase II trials of AM for inflammatory bowel diseases have been recently completed. The current AdrenoMedullin For Ischemic Stroke (AMFIS) study aims to assess the safety and efficacy of AM in patients with acute ischemic stroke.
The AMFIS study is an investigator-initiated, randomized, double-blind, phase-II trial. AM or placebo will be administered to patients with non-cardioembolic ischemic stroke within 24 h after stroke onset. In the first cohort of the AMFIS study, patients will be randomly allocated to the investigation treatment A (30 μg/kg of AM in total for 7 days, n = 20) or placebo group (n = 10). In the second cohort, patients will be assigned to the investigation treatment B (56 μg/kg of AM in total for 7 days, n = 20) or placebo group (n = 10).
Serious adverse events related to the protocol treatment will be evaluated as the primary outcome. All adverse events will be analyzed as the secondary outcome. Regarding efficacy endpoints, the change in National Institutes of Health Stroke Scale and modified Rankin Scale scores will be compared between investigation treatment and placebo groups.
AM is expected to be a safe and effective treatment for ischemic stroke.